The potential of melanoma antigen expression in cancer therapy.


:A potential new therapy for cancer is active specific immunotherapy with melanoma antigen (MAGE) gene products. The MAGE gene family comprizes a series of 12 closely related genes, some of which have been shown to be expressed in a variety of tumours of different histological origin. Peptides encoded by the MAGE genes are targets for specific immunotherapy as they are presented in association with human leucocyte antigen class I molecules and are recognised by cytotoxic T lymphocytes. This article reviews the discovery, development, role and therapeutic potential of MAGE tumour-associated antigens. Knowledge in this field of study is in its early stages. Future advances can be anticipated in term of defining therapeutic relevance, antigen detection and discovery of related genes.


Cancer Treat Rev


Cancer treatment reviews


Gillespie AM,Coleman RE





Has Abstract


1999-08-01 00:00:00














  • Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.

    abstract::Low Grade Serous Ovarian Carcinoma, LGSOC, is certainly a rare disease, accounting for only a small proportion of all ovarian carcinomas, nevertheless in the last decade we have acquired many data about its molecular and clinical features and it has been largely accepted that it has distinct pathogenesis, genetic aber...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Della Pepa C,Tonini G,Santini D,Losito S,Pisano C,Di Napoli M,Cecere SC,Gargiulo P,Pignata S

    更新日期:2015-02-01 00:00:00

  • DNA-based drug interactions of cisplatin.

    abstract::The interactions of cisplatin with other anti-cancer agents on the DNA level have been studied extensively in pre-clinical experiments. In general, combination of cisplatin with an antimetabolite, taxane, or topoisomerase inhibitor, can result in a modulation of platinum pharmacology on the DNA, for example, enhanced ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Crul M,van Waardenburg RC,Beijnen JH,Schellens JH

    更新日期:2002-12-01 00:00:00

  • Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.

    abstract::Antiangiogenic agents (AAs) have reported grater efficacy compared to interferon. Despite these advances, radiological complete response to therapy is rare. We meta-analyzed the incidence of complete response in patients treated with AAs and in controls in main randomized clinical trials for first-line therapy in meta...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审


    authors: Iacovelli R,Alesini D,Palazzo A,Trenta P,Santoni M,De Marchis L,Cascinu S,Naso G,Cortesi E

    更新日期:2014-03-01 00:00:00

  • Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.

    abstract::Historically, the median overall survival for patients with stage IV melanoma was less than 1 year and the 5-year survival rate was ∼10%. Recent advances in therapy have raised 5-year survival expectations to ∼20%. Notably, a subset of melanoma patients who receive immunotherapy with high-dose interleukin-2, and now i...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: McDermott D,Lebbé C,Hodi FS,Maio M,Weber JS,Wolchok JD,Thompson JA,Balch CM

    更新日期:2014-10-01 00:00:00

  • Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.

    abstract::Checkpoint blockades turn on a new paradigm shift in immunotherapy for cancer. Remarkable clinical efficacy, durable response and low toxicity of programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint blockades have been observed in various malignancies. However, a lot of cancer patients failed to resp...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Meng X,Huang Z,Teng F,Xing L,Yu J

    更新日期:2015-12-01 00:00:00

  • Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis.

    abstract:OBJECTIVES:To synthesize the evidence from randomized controlled trials concerning systemic treatment regimens for patients with cancer of unknown primary site (CUP). DATA SOURCES:PubMed and the Cochrane Library Central Registry of Controlled Trials. REVIEW METHODS:We retrieved all randomized controlled trials compar...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审


    authors: Golfinopoulos V,Pentheroudakis G,Salanti G,Nearchou AD,Ioannidis JP,Pavlidis N

    更新日期:2009-11-01 00:00:00

  • Adjuvant immunotherapy for non-small cell lung cancer.

    abstract::Non-small cell lung cancer (NSCLC) is the biggest cancer killer in the United States and worldwide. In 2011, there are estimated to be 221,130 new cases of lung cancer in the United States. Over a million people will die of lung cancer worldwide this year alone. When possible, surgery to remove the tumor is the best t...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Tucker ZC,Laguna BA,Moon E,Singhal S

    更新日期:2012-10-01 00:00:00

  • Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.

    abstract::Standard first-line treatment for metastatic castration-resistant prostate cancer (mCRPC) is docetaxel plus prednisone; however, patients will usually experience disease progression during or after docetaxel treatment due to inherent or acquired resistance. Before 2010, second-line options for mCRPC were limited. Howe...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Bahl A,Masson S,Birtle A,Chowdhury S,de Bono J

    更新日期:2014-02-01 00:00:00

  • Estrogen receptor-negative progesterone receptor-positive breast cancer - "Nobody's land" or just an artifact?

    abstract::The estrogen receptor α (ER) and the progesterone receptor (PgR) are one of the most important prognostic and predictive immunohistochemical markers in breast cancer. Breast cancers may express various profiles of hormone receptors: ER(+)/PgR(+), ER(-)/PgR(-), ER(+)/PgR(-) and ER(-)/PgR(+). The existence of the latter...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Kunc M,Biernat W,Senkus-Konefka E

    更新日期:2018-06-01 00:00:00

  • Improving attribution of adverse events in oncology clinical trials.

    abstract::Attribution of adverse events (AEs) is critical to oncology drug development and the regulatory process. However, processes for determining the causality of AEs are often sub-optimal, unreliable, and inefficient. Thus, we conducted a toxicity-attribution workshop in Silver Springs MD to develop guidance for improving ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: George GC,Barata PC,Campbell A,Chen A,Cortes JE,Hyman DM,Jones L,Karagiannis T,Klaar S,Le-Rademacher JG,LoRusso P,Mandrekar SJ,Merino DM,Minasian LM,Mitchell SA,Montez S,O'Connor DJ,Pettit S,Silk E,Sloan JA,Stewar

    更新日期:2019-06-01 00:00:00

  • Maintenance chemotherapy for non-small-cell lung cancer.

    abstract::Currently, platinum-based combination chemotherapy is the standard first-line chemotherapy for non-small-cell lung cancer (NSCLC). Historically, platinum-based chemotherapy has been recommended for up to six cycles even for responders, and second-line chemotherapy has been considered when disease progression is confir...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Kim YH,Mishima M

    更新日期:2011-11-01 00:00:00

  • PD-1 and PD-L1 blockade in gastrointestinal malignancies.

    abstract::Immunotherapy represents a major breakthrough in cancer therapy in recent years. Immune-checkpoint blockade using PD-1 and PD-L1 antibodies appears to be one of the most promising immunotherapy approaches. Immunotherapy differs from conventional cancer treatment because of its ability to produce durable responses in s...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Lote H,Cafferkey C,Chau I

    更新日期:2015-12-01 00:00:00

  • Molecular targeted therapy of glioblastoma.

    abstract::Glioblastomas are intrinsic brain tumors thought to originate from neuroglial stem or progenitor cells. More than 90% of glioblastomas are isocitrate dehydrogenase (IDH)-wildtype tumors. Incidence increases with age, males are more often affected. Beyond rare instances of genetic predisposition and irradiation exposur...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Le Rhun E,Preusser M,Roth P,Reardon DA,van den Bent M,Wen P,Reifenberger G,Weller M

    更新日期:2019-11-01 00:00:00

  • Developments in the systemic treatment of metastatic cervical cancer.

    abstract::Despite the available prevention and early detection strategies, advanced squamous-cell carcinoma of the uterine cervix remains a major concern for public health. Systemic treatment with cisplatin, either in combination with external beam irradiation for locally advanced disease, or as monotherapy for recurrent/metast...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Mountzios G,Soultati A,Pectasides D,Pectasides E,Dimopoulos MA,Papadimitriou CA

    更新日期:2013-08-01 00:00:00

  • Open conservation partial laryngectomy for laryngeal cancer: a systematic review of English language literature.

    abstract:BACKGROUND:Different modalities of treatment in early laryngeal cancer lead to equivalent oncological outcomes. Hence this systematic review was undertaken to synthesise the key oncological outcomes following primary open partial laryngectomy for laryngeal cancer. METHODS:A systematic review of the English literature ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审


    authors: Thomas L,Drinnan M,Natesh B,Mehanna H,Jones T,Paleri V

    更新日期:2012-05-01 00:00:00

  • Prostate-specific antigen kinetics as a surrogate endpoint in clinical trials of metastatic castration-resistant prostate cancer: a review.

    abstract::Prostate cancer is the most common cancer in men. Overall survival is considered the best endpoint for clinical trials, but it is difficult to use in phase-2 studies. Although the reduction of PSA after cytotoxic chemotherapy has been identified as a valid surrogate for overall survival, it has not proven reliable for...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Colloca G

    更新日期:2012-12-01 00:00:00

  • Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC).

    abstract::While chemotherapy has been the standard of care for patients with advanced non-small cell lung cancer (NSCLC), efforts have shifted toward evaluating novel targeted agents in an attempt to improve outcome. These targeted agents are directed toward key components in several signalling pathways such as vascular endothe...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Belani CP,Goss G,Blumenschein G Jr

    更新日期:2012-05-01 00:00:00

  • Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR.

    abstract::In metastatic colorectal cancer (mCRC), fluorouracil-based combination therapy with oxaliplatin or irinotecan is the mainstay of first-line treatment. Patient survival has been significantly improved with the introduction of monoclonal antibodies against VEGF (bevacizumab), VEGFR2 (ramucirumab) or EGFR (cetuximab or p...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Sartore-Bianchi A,Siena S,Tonini G,Bardelli A,Santini D

    更新日期:2016-12-01 00:00:00

  • Unraveling galectin-1 as a novel therapeutic target for cancer.

    abstract::Galectins belong to a family of carbohydrate-binding proteins with an affinity for β-galactosides. Galectin-1 is differentially expressed by various normal and pathologic tissues and displays a wide range of biological activities. In oncology, galectin-1 plays a pivotal role in tumor growth and in the multistep proces...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Astorgues-Xerri L,Riveiro ME,Tijeras-Raballand A,Serova M,Neuzillet C,Albert S,Raymond E,Faivre S

    更新日期:2014-03-01 00:00:00

  • An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma.

    abstract::Malignant Pleural Mesothelioma (MPM) is an aggressive tumour with poor prognosis and increasing incidence in industrialized countries because of the previous widespread exposure to asbestos fibres and to the long lag period from time of exposure and the diagnosis of the disease. MPM shows high refractoriety to systemi...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Pasello G,Ceresoli GL,Favaretto A

    更新日期:2013-02-01 00:00:00

  • Intraperitoneal chemotherapy in ovarian cancer.

    abstract::From a theoretical viewpoint, intraperitoneal therapy (IP) in patients with ovarian cancer, a malignancy which remains mainly confined to the peritoneal cavity, is logical. Over the past decades this approach has evolved into a therapeutic strategy for a selected group of patients. Data available at present suggest a ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章


    authors: Hofstra LS,de Vries EG,Mulder NH,Willemse PH

    更新日期:2000-04-01 00:00:00

  • Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling.

    abstract::Acute myeloid leukemia (AML) presents therapeutic challenges in older adults because of high-risk leukemia biology conferring chemoresistance, and poor functional status resulting in increased therapy-related toxicities. Recent FDA approval of 8 new drugs for AML has increased therapeutic armamentarium and also provid...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Bhatt VR

    更新日期:2019-05-01 00:00:00

  • Phase I study and pharmacokinetics of intraperitoneal carboplatin.

    abstract::In the early stages of this phase I study the tolerance of carboplatin intraperitoneally was good. Pharmacokinetic profiles suggest a possible therapeutic advantage for giving the drug intraperitoneally for the treatment of tumour nodules situated in the peritoneum. The extent of penetration of carboplatin through tum...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章


    authors: McVie JG,ten Bokkel Huinink W,Dubbelman R,Franklin H,van der Vijgh W,Klein I

    更新日期:1985-09-01 00:00:00

  • Clinical predictors of benefit from fulvestrant in advanced breast cancer: A Meta-analysis of randomized controlled trials.

    abstract:BACKGROUND:Data on the comparative efficacy of fulvestrant and other endocrine treatments are inconsistent. Clinical markers predictive of greater benefit from fulvestrant compared to the alternate endocrine agents have not been identified. METHODS:We searched the literature from inception to May 2015, using MEDLINE, ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审


    authors: Graham J,Pitz M,Gordon V,Grenier D,Amir E,Niraula S

    更新日期:2016-04-01 00:00:00

  • Swallowing dysfunction in head and neck cancer patients treated by radiotherapy: review and recommendations of the supportive task group of the Italian Association of Radiation Oncology.

    abstract:PURPOSE:Dysphagia is a debilitating complication in head and neck cancer patients (HNCPs) that may cause a high mortality rate for aspiration pneumonia. The aims of this paper were to summarize the normal swallowing mechanism focusing on its anatomo-physiology, to review the relevant literature in order to identify the...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Russi EG,Corvò R,Merlotti A,Alterio D,Franco P,Pergolizzi S,De Sanctis V,Ruo Redda MG,Ricardi U,Paiar F,Bonomo P,Merlano MC,Zurlo V,Chiesa F,Sanguineti G,Bernier J

    更新日期:2012-12-01 00:00:00

  • Comparison of radiological criteria for hyperprogressive disease in response to immunotherapy.

    abstract::Hyperprogressive disease (HPD) is a concerning paradoxical acceleration of cancer growth induced by immune drugs. The lack of standard radiological criteria makes its study challenging. We reviewed the literature and compared the main criteria for HPD proposed by Ferté, Le Tourneau, Garralda and Caramella to address t...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Gomes da Morais AL,de Miguel M,Cardenas JM,Calvo E

    更新日期:2020-12-01 00:00:00

  • The sentinel node negative axilla: is it a no-go zone?

    abstract::The technique of sentinel node biopsy (SNB) presents a great opportunity to reduce the morbidity of surgical treatment of breast cancer. Using either dye, isotope or a combination, after completing a learning process a sensitivity of 80-99% may be achieved. Most surgeons would aim for a sensitivity of 95% but this wil...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章


    authors: Fentiman IS,Mansel RE

    更新日期:2002-02-01 00:00:00

  • Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: A systematic review and meta-analysis.

    abstract:PURPOSE:Neoadjuvant chemotherapy followed by surgery (NACT + S) has been compared with definitive chemoradiothherapy (CRT) in randomized clinical trials (RCTs) in stage IB2, IIA and IIB cervical cancer (1994 Figo stage). Our aim was to evaluate efficacy and toxicity of NACT + S and CRT and identify differences in clini...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析


    authors: Marchetti C,Fagotti A,Tombolini V,Scambia G,De Felice F

    更新日期:2020-02-01 00:00:00

  • Effects of hormonal treatment on lipids in patients with cancer.

    abstract::Patients with malignant disease may need hormonal therapy as primary or adjuvant treatment or for palliation. Oestrogens usually decrease serum levels of total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C), increase high density lipoprotein cholesterol (HDL-C) concentration, but induce an elevation ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Filippatos TD,Liberopoulos EN,Pavlidis N,Elisaf MS,Mikhailidis DP

    更新日期:2009-04-01 00:00:00

  • Current questions for the treatment of advanced gastric cancer.

    abstract:BACKGROUND:Gastric cancer remains a major health problem worldwide. Treatment of advanced gastric cancer is controversial and there is no standard regimen for first- or second-line chemotherapy (CT). This review aims to give an overview of the hot topics concerning treatment, prognostic factors and new strategies in ad...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Cervantes A,Roda D,Tarazona N,Roselló S,Pérez-Fidalgo JA

    更新日期:2013-02-01 00:00:00